Incyte Stock Today

INCY Stock  USD 57.34  1.03  1.76%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Less than 2

 
100  
 
Zero
Very Low
Incyte is trading at 57.34 as of the 19th of March 2024; that is -1.76 percent decrease since the beginning of the trading day. The stock's open price was 58.37. Incyte has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Incyte are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 18th of February 2024 and ending today, the 19th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
4th of November 1993
Category
Healthcare
Classification
Health Care
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. The company has 224.53 M outstanding shares of which 7.77 M shares are currently shorted by private and institutional investors with about 4.45 trading days to cover. More on Incyte

Moving together with Incyte Stock

  0.75VALN Valneva SE ADR Earnings Call TomorrowPairCorr
  0.64FLGC Flora Growth Corp Report 29th of March 2024 PairCorr

Moving against Incyte Stock

  0.74ALVO Alvotech Earnings Call This WeekPairCorr
  0.61MRK Merck Company Sell-off TrendPairCorr
  0.56REGN Regeneron Pharmaceuticals Financial Report 2nd of May 2024 PairCorr
  0.49APGE Apogee TherapeuticsPairCorr

Incyte Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Incyte's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Incyte or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Incyte's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Incyte's managers, analysts, and investors.
Environment Score
Governance Score
Social Score
ChairmanJulian Baker
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP 500 Index, NASDAQ Biotechnology, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Excise Tax ActivitiesAnimal Testing
Average Analyst Recommendation
Analysts covering Incyte report their recommendations after researching Incyte's financial statements, talking to executives and customers, or listening in on Incyte's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Incyte. The Incyte consensus assessment is calculated by taking the average forecast from all of the analysts covering Incyte.
Financial Strength
Based on the measurements of operating efficiency obtained from Incyte's historical financial statements, Incyte is performing exceptionally good at this time. It has a great odds to report excellent financial results in April. Financial strength of Incyte is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.320.5449
Way Down
Pretty Stable
Gross Profit Margin1.390.931
Way Up
Slightly volatile
Total Current Liabilities1.3 B1.2 B
Sufficiently Up
Slightly volatile
Non Current Liabilities Total340.4 M351.9 M
Sufficiently Down
Pretty Stable
Total Assets7.1 B6.8 B
Sufficiently Up
Slightly volatile
Total Current Assets4.9 B4.6 B
Sufficiently Up
Slightly volatile
Incyte's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Incyte's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Incyte's financial leverage. It provides some insight into what part of Incyte's total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Incyte's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Incyte deploys its capital and how much of that capital is borrowed.
Liquidity
Incyte cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 38.29 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Incyte has a current ratio of 3.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Incyte until it has trouble settling it off, either with new capital or with free cash flow. So, Incyte's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Incyte sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Incyte to invest in growth at high rates of return. When we think about Incyte's use of debt, we should always consider it together with cash and equity.

Total Cash From Financing Activities

(19.03 Million)
Incyte (INCY) is traded on NASDAQ Exchange in USA. It is located in 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 and employs 2,524 people. Incyte is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 13.11 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Incyte's market, we take the total number of its shares issued and multiply it by Incyte's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Incyte conducts business under Biotechnology sector and is part of Health Care industry. The entity has 224.53 M outstanding shares of which 7.77 M shares are currently shorted by private and institutional investors with about 4.45 trading days to cover. Incyte currently holds about 2.72 B in cash with 496.49 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.24.
Check Incyte Probability Of Bankruptcy
Ownership Allocation
Incyte secures a total of 224.53 Million outstanding shares. The majority of Incyte outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Incyte to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Incyte. Please pay attention to any change in the institutional holdings of Incyte as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Incyte Ownership Details

Incyte Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Incyte jumping above the current price in 90 days from now is more than 93.0%. The Incyte probability density function shows the probability of Incyte stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Incyte has a beta of 0.637. This usually indicates as returns on the market go up, Incyte average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Incyte will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Incyte is significantly underperforming NYSE Composite.
  Odds Below 57.34HorizonTargetOdds Above 57.34
6.53%90 days
 57.34 
93.38%
Based on a normal probability distribution, the odds of Incyte to move above the current price in 90 days from now is more than 93.0 (This Incyte probability density function shows the probability of Incyte Stock to fall within a particular range of prices over 90 days) .

Incyte Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Incyte that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Incyte's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Incyte's value.
InstituionRecorded OnShares
Lsv Asset Management2023-12-31
2.7 M
Man Group Plc2023-12-31
2.4 M
Goldman Sachs Group Inc2023-12-31
2.4 M
Pictet Asset Manangement Sa2023-12-31
2.3 M
Bellevue Group Ag2023-12-31
2.2 M
Jacobs Levy Equity Management, Inc.2023-09-30
2.1 M
Northern Trust Corp2023-12-31
M
Norges Bank2023-12-31
M
Legal & General Group Plc2023-12-31
M
Baker Bros Advisors Lp2023-12-31
36.2 M
Blackrock Inc2023-12-31
24.3 M
View Incyte Diagnostics

Incyte Historical Income Statement

Incyte Income Statement is one of the three primary financial statements used for reporting Incyte's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Incyte revenue and expense. Incyte Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Incyte's Total Other Income Expense Net is fairly stable compared to the past year. Net Income is likely to rise to about 627.5 M in 2024, whereas Interest Expense is likely to drop slightly above 2.4 M in 2024. View More Fundamentals

Incyte Stock Against Markets

Picking the right benchmark for Incyte stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Incyte stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Incyte is critical whether you are bullish or bearish towards Incyte at a given time. Please also check how Incyte's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Incyte without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Economic Indicators Now

   

Economic Indicators

Top statistical indicators that provide insights into how an economy is performing
All  Next Launch Module

Incyte Corporate Directors

Incyte corporate directors refer to members of an Incyte board of directors. The board of directors generally takes responsibility for the Incyte's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Incyte's board members must vote for the resolution. The Incyte board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.

How to buy Incyte Stock?

Before investing in Incyte, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Incyte. To buy Incyte stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Incyte. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Incyte stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Incyte stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Incyte stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Incyte, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.

Already Invested in Incyte?

The danger of trading Incyte is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Incyte is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Incyte. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Incyte is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Incyte offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Incyte's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Incyte Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Incyte Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.
Note that the Incyte information on this page should be used as a complementary analysis to other Incyte's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Incyte Stock analysis

When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Stocks Directory
Find actively traded stocks across global markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Is Incyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incyte. If investors know Incyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
6.324
Earnings Share
2.65
Revenue Per Share
16.526
Quarterly Revenue Growth
0.093
Return On Assets
0.0646
The market value of Incyte is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte's value that differs from its market value or its book value, called intrinsic value, which is Incyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte's market value can be influenced by many factors that don't directly affect Incyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Incyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.